Searching for multi-targeting neurotherapeutics against Alzheimer's: Discovery of potent AChE-MAO B inhibitors through the decoration of the 2H-Chromen-2-one structural motif

Molecules

Volumn 21, Issue 3, 2016, Pages

  Pisani, Leonardo ^a   Farina, Roberta ^a   Soto Otero, Ramon ^b   Denora, Nunzio ^a   Mangiatordi, Giuseppe Felice ^a   Nicolotti, Orazio ^a   Mendez Alvarez, Estefania ^b   Altomare, Cosimo Damiano ^a   Catto, Marco ^a   Carotti, Angelo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Coumarins; MAO inhibitors; Multi target directed ligands

Indexed keywords

CHOLINESTERASE INHIBITOR; MONOAMINE OXIDASE INHIBITOR;

ALZHEIMER DISEASE; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYME ACTIVATION; HUMAN; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ALZHEIMER DISEASE; ANIMALS; CELL LINE; CHOLINESTERASE INHIBITORS; DRUG DISCOVERY; ENZYME ACTIVATION; HUMANS; MOLECULAR STRUCTURE; MONOAMINE OXIDASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84963665012     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21030362     Document Type: Article

References (31)

1. Querfurth, H.W.; LaFerla, F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362, 329-344. [CrossRef] [PubMed]
2. Giacobini, E. Cholinesterase inhibitors stabilize Alzheimer's disease. Neurochem. Res. 2000, 25, 1185-1190. [CrossRef] [PubMed]
3. Lipton, S.A. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: Low-affinity, uncompetitive antagonism. Curr. Alzheimer Res. 2005, 2, 155-165. [CrossRef] [PubMed]
4. Carreiras, M.C.; Mendes, E.; Perry, M.J.; Francisco, A.P.; Marco-Contelles, J. The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr. Top. Med. Chem. 2013, 13, 1745-1770. [CrossRef] [PubMed]
5. Leon, R.; Garcia, A.G.; Marco-Contelles, J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. Med. Res. Rev. 2013, 33, 139-189. [CrossRef] [PubMed]
6. Berk, C.; Sabbagh, M.N. Successes and failures for drugs in late-stage development for Alzheimer's disease. Drugs Aging 2013, 30, 783-792. [CrossRef] [PubMed]
7. Gu, F.; Zhu, M.; Shi, J.; Hu, Y.; Zhao, Z. Enhanced oxidative stress is an early event during development of Alzheimer-like pathologies in presenilin conditional knock-out mice. Neurosci. Lett. 2008, 440, 44-48. [CrossRef] [PubMed]
8. Pisani, L.; Catto, M.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Campagna, F.; Carotti, A. Targeting monoamine oxidases with multipotent ligands: An emerging strategy in the search of new drugs against neurodegenerative diseases. Curr. Med. Chem. 2011, 18, 4568-4587. [CrossRef] [PubMed]
9. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D.E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO-A): Relation to the structures of rat MAO-A and human MAO-B. Proc. Natl. Acad. Sci. USA 2005, 102, 12684-12689. [CrossRef] [PubMed]
10. Riederer, P.; Danielczyk, W.; Gruenblatt, E. Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology 2004, 1-2, 271-277. [CrossRef]
11. Pisani, L.; Catto, M.; Nicolotti, O.; Grossi, G.; di Braccio, M.; Soto-Otero, R.; Mendez-Alvarez, E.; Stefanachi, A.; Gadaleta, D.; Carotti, A. Fine molecular tuning at position 4 of 2H-chromen-2-one derivatives in the search of potent and selective monoamine oxidase B inhibitors. Eur. J. Med. Chem. 2013, 70, 723-739. [CrossRef] [PubMed]
12. Pisani, L.; Muncipinto, G.; Miscioscia, T.F.; Nicolotti, O.; Leonetti, F.; Catto, M.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; et al. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: Development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor. J. Med. Chem. 2009, 52, 6685-6706.
13. Pisani, L.; Farina, R.; Nicolotti, O.; Gadaleta, D.; Soto-Otero, R.; Catto, M.; di Braccio, M.; Mendez-Alvarez, E.; Carotti, A. In silico design of novel 2H-chromen-2-one derivatives as potent and selective MAO-B inhibitors. Eur. J. Med. Chem. 2015, 89, 98-105. [CrossRef] [PubMed]
14. Catto, M.; Pisani, L.; Leonetti, F.; Nicolotti, O.; Pesce, P.; Stefanachi, A.; Cellamare, S.; Carotti, A. Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. Bioorg. Med. Chem. 2013, 21, 146-152. [CrossRef] [PubMed]
15. Farina, R.; Pisani, L.; Catto, M.; Nicolotti, O.; Gadaleta, D.; Denora, N.; Soto-Otero, R.; Mendez-Alvarez, E.; Passos, C.S.; Muncipinto, G.; et al. Structure-based design and optimization of multitarget-directed 2H-chromen-2-one derivatives as potent inhibitors of monoamine oxidase B and cholinesterases. J. Med. Chem. 2 2015, 58, 5561-5578. [CrossRef] [PubMed]
16. Pisani, L.; Catto, M.; Giangreco, I.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Cellamare, S.; Carotti, A. Design, synthesis and biological evaluation of coumarin derivatives tethered to an edrophonium-like fragment as highly potent and selective dual binding site acetylcholinesterase inhibitors. Chem. Med. Chem. 2010, 5, 1616-1630. [CrossRef] [PubMed]
17. Harayama, T.; Katsuno, K.; Nishioka, N.; Fujii, M.; Nishita, Y.; Isii, H.; Kaneko, Y. A convenient synthesis of a simple coumarin from salicylaldehyde and Witting reagent (I): A synthesis of methoxy- and hydroxycoumarins. Heterocycles 1994, 39, 613-622. [CrossRef]
18. Cai, X.; Yang, J.; Zhou, J.; Lu, W.; Hu, C.; Gu, Z.; Huo, J.; Wang, X.; Cao, P. Synthesis and biological evaluation of scopoletin derivatives. Bioorg. Med. Chem. 2013, 21, 84-92. [CrossRef] [PubMed]
19. Youdim, M.B.H.; Gross, A.; Finberg, J.P.M. Rasagiline [N-propargyl-1R(+)aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 2001, 132, 500-506. [CrossRef] [PubMed]
20. Ellman, G.L.; Courtney, K.D.; Andres, V., Jr.; Feartherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95. [CrossRef]
21. Pisani, L.; Barletta, M.; Soto-Otero, R.; Nicolotti, O.; Mendez-Alvarez, E.; Catto, M.; Introcaso, A.; Stefanachi, A.; Cellamare, S.; Altomare, C.D.; et al. Carotti, A.; et al. Discovery, biological evaluation, and structure-activity and -selectivity relationships of 6′-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N-methylacetamides, a novel class of potent and selective monoamine oxidase inhibitors. J. Med. Chem. 2013, 56, 2651-2664. [CrossRef] [PubMed]
22. Denizot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 1986, 89, 271-277. [CrossRef]
23. Li, N.; Ragheb, K.; Lawler, G.; Sturgis, J.; Rajwa, B.; Melendez, J.A.; Robinson, J.P. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 2003, 278, 8516-8525. [CrossRef] [PubMed]
24. Denora, N.; Laquintana, V.; Trapani, A.; Lopedota, A.; Latrofa, A.; Gallo, J.M.; Trapani, G. Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential. Mol. Pharm. 2010, 7, 2255-2269. [CrossRef] [PubMed]
25. Denora, N.; Cassano, T.; Laquintana, V.; Lopalco, A.; Trapani, A.; Cimmino, C.S.; Laconca, L.; Giuffrida, A.; Trapani, G. Novel codrugs with GABAergic activity for dopamine delivery in the brain. Int. J. Pharm. 2012, 437, 221-231. [CrossRef] [PubMed]
26. Leonetti, F.; Favia, A.; Rao, A.; Aliano, R.; Paluszcak, A.; Hartmann, R.W.; Carotti, A. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. J. Med. Chem. 2004, 47, 6792-6803. [CrossRef] [PubMed]
27. Tan, Y.; Yang, X.D.; Liu, W.J.; Sun, X.W. Novel one-pot asymmetric cascade approach toward densely substituted enantioenriched α-methylene-γ-lactams. Tetrahedron Lett. 2014, 55, 6105-6108. [CrossRef]
28. Mendez-Alvarez, E.; Soto-Otero, R.; Sanchez-Sellero, I.; Lopez-Rivadulla, L.M.; Lamas, M. Inhibition of brain monoamine oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke. Life Sci. 1997, 60, 1719-1727. [CrossRef]
29. Conejo-Garcia, A.; Pisani, L.; Nunez, M.C.; Catto, M.; Nicolotti, O.; Leonetti, F.; Campos, J.M.; Gallo, M.A.; Espinosa, A.; Carotti, A. Homodimeric bis-quaternary heterocyclic ammonium salts as potent acetyl- and butyrylcholinesterase inhibitors: A systematic investigation of the influence of linker and cationic heads over affinity and selectivity. J. Med. Chem. 2011, 54, 2627-2645. [CrossRef] [PubMed]
30. Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmonson, D.E.; Mattevi, A. Binding of rasagiline-related inhibitors to human monoamine oxidases: A kinetic and crystallographic analysis. J. Med. Chem. 2005, 48, 8148-8154. [CrossRef] [PubMed]
31. Zindo, F.T.; Joubert, J.; Malan, S.F. Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond. Future Med. Chem. 2015, 7, 609-629. [CrossRef] [PubMed]